Get started
Author

Kayla N. Kleist

Observed names: K. Kleist, Kayla Kleist
OpenAlex ID: A5045831752
Povetacicept, an Enhanced Dual APRIL / BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases
2023 · Lawrence S. Evans, Katherine E. Lewis, et al. · Arthritis & Rheumatology · 70
PDF
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
2022 · Mark F. Maurer, Katherine E. Lewis, et al. · Nature Communications · 45
PDF
Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept ( ALPN ‐101)
2023 · Stacey R. Dillon, Lawrence S. Evans, et al. · Arthritis & Rheumatology · 15
PDF
ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS
2024 · Andrée-Anne Berthiaume, Sherif M. Reda, et al. · Frontiers in Neuroscience · 4
Op0039 Alpn-303, an Enhanced, Potent Dual Baff/april Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (sle) and Other B Cell-related Autoimmune Diseases
2021 · S.R. Dillon, L.S. Evans, et al. · Annals of the Rheumatic Diseases · 4
PDF
Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease (S26.008)
2023 · Hans Moebius, Kai-Bin Ooi, et al. · Neurology · 3
Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease
2023 · Hans J. Moebius, Kai‐Bin C. Ooi, et al. · Alzheimer s & Dementia · 1
Pos0094 Alpn-303, an Engineered Dual Baff/april Antagonist, Potently Inhibits Pathogenic Lymphocyte Subsets and Function in B-cell- and Antibody-related Preclinical Models
2022 · S.R. Dillon, K.E. Lewis, et al. · Annals of the Rheumatic Diseases · 1
PDF
ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole
2026 · Andrée-Anne Berthiaume, Kayla N. Kleist, et al. · Frontiers in Neurology
Development of Novel Small Molecules Targeting Neurotrophic HGF Signaling for the Treatment of Alzheimer’s, Parkinson’s, and ALS
2024 · Robert W. Taylor, Andree-Anne Berthiaume, et al. · Neurotherapeutics
PDF
Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders (P11-4.003)
2024 · Kevin Church, Sherif Reda, et al. · Neurology
ATH‐1105, a small molecule positive modulator of the HGF/MET system, is neuroprotective and attenuates TDP‐43 protein pathology in ALS and frontotemporal dementia‐relevant preclinical models
2023 · Jewel L Johnston, Andrée‐Anne Berthiaume, et al. · Alzheimer s & Dementia
PDF
Small Molecule Positive Modulator of Hepatocyte Growth Factor (HGF)/MET, ATH-1105, Improves Function and Reduces Disease Biomarkers in a TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis (P8-8.007)
2023 · Kayla Kleist, Andree-Anne Berthiaume, et al. · Neurology
Abstract 1740: Engineered variant domain fusion proteins provide checkpoint inhibition and tumor antigen dependent CD28 costimulation resulting in potent anti-tumor immunity
2021 · Steven D. Levin, Mark F. Maurer, et al. · Cancer Research
Abstract LB-085: ALPN-202 combines checkpoint inhibition with conditional T cell costimulation to overcome T cell suppression by M2c macrophages and improve the durability of engineered T cell anti-tumor responses
2020 · Mark F. Maurer, Siddarth Chandrasekaran, et al. · Cancer Research
Thu0222 B Cell Modulatory Variant Tnf Receptor Domains (vtds) Identified by Directed Evolution to Inhibit Baff and April, Alone or Combined With Variant Ig Domains (vigd™) That Inhibit T Cell Costimulation, for the Treatment of Severe Autoimmune And/or Inflammatory Disease
2020 · S.R. Dillon, L.S. Evans, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 16
Citation count: 143
H-index: 4
I10-index: 3
Year
Topic
Type